嘉必優(688089.SH):蘇州鼎石匯澤生物產業投資基金已完成工商登記
格隆匯 8 月 4日丨嘉必優(688089.SH)公佈,公司與鼎石匯澤、振華股份共同設立蘇州鼎石匯澤生物產業投資基金合夥企業(有限合夥)。《蘇州鼎石匯澤生物產業投資基金合夥企業(有限合夥)合夥協議》(以下簡稱"合夥協議")已經簽署,基金規模20,000萬元,其中鼎石匯澤以普通合夥人身份認繳出資200萬元人民幣,認繳比例為1%;公司以有限合夥人身份認繳出資9,900萬元人民幣,認繳比例為49.5%;振華股份以有限合夥人身份認繳出資9,900萬元人民幣,認繳比例為49.5%。
公司近日收到蘇州鼎石匯澤生物產業投資基金合夥企業(有限合夥)的通知,其已於2020年8月3日完成工商登記。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.